Catabasis Pharmaceuticls Inc. (CATB) Rating Reiterated by Wedbush
Catabasis Pharmaceuticls Inc. (NASDAQ:CATB)‘s stock had its “outperform” rating restated by research analysts at Wedbush in a research report issued to clients and investors on Monday. They currently have a $17.00 price objective on the stock, up from their prior price objective of $15.00. Wedbush’s target price points to a potential upside of 276.11% from the company’s current price.
Separately, Zacks Investment Research lowered shares of Catabasis Pharmaceuticls from a “buy” rating to a “hold” rating in a research report on Monday, July 18th. Five equities research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average target price of $19.20.
Shares of Catabasis Pharmaceuticls (NASDAQ:CATB) opened at 4.52 on Monday. Catabasis Pharmaceuticls has a 52 week low of $3.22 and a 52 week high of $10.83. The company’s 50-day moving average is $4.53 and its 200 day moving average is $4.60. The firm’s market capitalization is $69.52 million.
Catabasis Pharmaceuticls (NASDAQ:CATB) last issued its quarterly earnings results on Thursday, November 10th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.11. Analysts anticipate that Catabasis Pharmaceuticls will post ($2.32) EPS for the current fiscal year.
Several large investors have recently added to or reduced their stakes in the company. Bridgeway Capital Management Inc. acquired a new stake in Catabasis Pharmaceuticls during the second quarter valued at about $102,000. Tocqueville Asset Management L.P. acquired a new stake in Catabasis Pharmaceuticls during the third quarter valued at about $123,000. Gilder Gagnon Howe & Co. LLC acquired a new stake in Catabasis Pharmaceuticls during the third quarter valued at about $138,000. TLP Group LLC acquired a new stake in Catabasis Pharmaceuticls during the third quarter valued at about $160,000. Finally, Great Point Partners LLC acquired a new stake in Catabasis Pharmaceuticls during the third quarter valued at about $1,540,000. 56.17% of the stock is owned by institutional investors.
Catabasis Pharmaceuticls Company Profile
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Stock Ratings for Catabasis Pharmaceuticls Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticls Inc. and related stocks with our FREE daily email newsletter.